Benzinga · Mar 5, 2026
Wedbush Maintains Outperform on TScan Therapeutics, Raises Price Target to $5
Wedbush analyst David Nierengarten maintains TScan Therapeutics (NASDAQ:TCRX) with a Outperform and raises the price target from $4 to $5.
TC
NASDAQ · TCRX
TScan Therapeutics, Inc.
Healthcare · Biotechnology
$0.28
Up+$0.00 (+0.54%)
Updated Oct 7, 2026, 8:14 PM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 61.01M
- P/E ratio
- -1.02
- Dividend yield
- 0.00%
- 52-week range
- $0.29 – $1.47
- Volume
- 609.55K
- Avg. volume
- 792.82K
Price performance · TCRX
TCRX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
TCRX closed at $0.28 after 21 trading sessions, down 20.13% for the selected period.
- Last close
- $0.28
- Period change
- -20.13%
- Period low
- $0.28
- Period high
- $0.36
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $0.2927 | $0.2965 | $0.2643 | $0.2754 | 609.55K |
| Oct 5, 2026 | $0.3169 | $0.33 | $0.285 | $0.2953 | 758.2K |
| Oct 2, 2026 | $0.33 | $0.33 | $0.3155 | $0.3205 | 151.98K |
| Oct 1, 2026 | $0.319 | $0.3288 | $0.3109 | $0.3175 | 624.8K |
| Sep 30, 2026 | $0.3222 | $0.345 | $0.3145 | $0.3145 | 554.41K |
| Sep 29, 2026 | $0.3387 | $0.346 | $0.3114 | $0.3175 | 753.47K |
| Sep 28, 2026 | $0.34 | $0.3478 | $0.3251 | $0.34 | 359.2K |
| Sep 25, 2026 | $0.3521 | $0.37 | $0.33 | $0.34 | 382.31K |
| Sep 24, 2026 | $0.369 | $0.369 | $0.34 | $0.349 | 606.69K |
| Sep 23, 2026 | $0.36 | $0.3718 | $0.341 | $0.364 | 1.08M |
| Sep 22, 2026 | $0.3333 | $0.3595 | $0.3302 | $0.3548 | 918.45K |
| Sep 21, 2026 | $0.3113 | $0.3417 | $0.3113 | $0.3306 | 756.92K |
| Sep 18, 2026 | $0.3427 | $0.3571 | $0.3095 | $0.3119 | 1.14M |
| Sep 17, 2026 | $0.335 | $0.3624 | $0.3244 | $0.3335 | 1.1M |
| Sep 16, 2026 | $0.33 | $0.34 | $0.3213 | $0.331 | 884.12K |
| Sep 15, 2026 | $0.3161 | $0.322 | $0.2902 | $0.3213 | 679.17K |
| Sep 14, 2026 | $0.3204 | $0.3343 | $0.3058 | $0.3063 | 1.1M |
| Sep 11, 2026 | $0.3242 | $0.325 | $0.3055 | $0.3204 | 873.12K |
| Sep 10, 2026 | $0.3202 | $0.3498 | $0.31 | $0.3179 | 804.59K |
| Sep 9, 2026 | $0.34 | $0.3425 | $0.33 | $0.3301 | 704.85K |
| Sep 8, 2026 | $0.38 | $0.38 | $0.33 | $0.3448 | 1.54M |
Latest TCRX news
The latest Smart Investors Daily articles mentioning TCRX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TCRX research
Overview
Company profile and research snapshot.
Company profile
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $7.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 8, 2026 | HC Wainwright & Co. | Neutral | — |
| Sep 3, 2026 | Wedbush | Neutral | — |
| Sep 2, 2026 | Needham | Hold | — |
| Aug 12, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 23, 2026 | Wedbush | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 4, 2026
Earnings Breakdown: TScan Therapeutics Q4
Benzinga · Mar 4, 2026
TScan Therapeutics' Cash And Cash Equivalents Of $152.4M To Provide Cash Runway Into 2H Of 2027
Benzinga · Mar 4, 2026
TScan Therapeutics Q4 2025 EPS $(0.18) Beats $(0.24) Estimate, Sales $2.567M Beat $2.048M Estimate
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
